BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases
OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photorecept…